Spyglass Capital Management LLC Lowers Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Spyglass Capital Management LLC lessened its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 652,841 shares of the biotechnology company's stock after selling 10,047 shares during the period. Ascendis Pharma A/S comprises 6.4% of Spyglass Capital Management LLC's holdings, making the stock its 2nd largest position. Spyglass Capital Management LLC owned approximately 1.08% of Ascendis Pharma A/S worth $97,476,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of ASND. Westfield Capital Management Co. LP boosted its holdings in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock worth $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock worth $572,341,000 after buying an additional 229,995 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock worth $278,760,000 after buying an additional 155,971 shares during the last quarter. Fred Alger Management LLC grew its holdings in shares of Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company's stock valued at $41,879,000 after acquiring an additional 120,952 shares in the last quarter. Finally, Tri Locum Partners LP increased its position in shares of Ascendis Pharma A/S by 102.1% in the second quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company's stock valued at $31,062,000 after acquiring an additional 115,092 shares during the last quarter.

Ascendis Pharma A/S Stock Down 0.2 %

Shares of Ascendis Pharma A/S stock traded down $0.24 on Friday, hitting $136.08. The stock had a trading volume of 491,960 shares, compared to its average volume of 451,948. The stock has a market cap of $8.25 billion, a price-to-earnings ratio of -16.87 and a beta of 0.66. Ascendis Pharma A/S has a twelve month low of $97.86 and a twelve month high of $161.00. The business's 50 day moving average is $132.21 and its two-hundred day moving average is $132.24.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. As a group, equities analysts predict that Ascendis Pharma A/S will post -7.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ASND. StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Jefferies Financial Group upped their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a "buy" rating in a research report on Tuesday, August 13th. Wells Fargo & Company lifted their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research report on Tuesday, September 17th. Bank of America upped their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Finally, Wedbush reiterated an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.